Jun 1, 2026 · 2h 48m
Clinicians warn of sourcing risks amid the rapid rise of peptide therapeutics
Peptides: The Science, Uses & Safety | Dr. Abud Bakri
As peptides gain mainstream popularity for healing and longevity, understanding the science and safety risks is crucial to avoiding contaminated products and ineffective treatments.
- 1Sourcing safety and regulatory compliance are critical when navigating the rapidly evolving peptide market.
- 2Compounds like BPC-157 and GLP-1 agonists show therapeutic promise but require careful clinical oversight.
- 3Bridging the gap between animal data and human trials is essential for safe peptide adoption.
Don't miss
Dr. Abud Bakri details the therapeutic potential and regulatory hurdles of tissue-repairing compounds like BPC-157.
The brief
Peptides are transforming modern medicine, offering targeted interventions for tissue repair, metabolic dysfunction, and longevity, yet their rapid rise has outpaced regulatory frameworks and robust human clinical trials.
Dr. Abud Bakri explains that while compounds like BPC-157 and GLP-1 agonists show immense clinical promise, the lack of human data means patients must navigate a landscape filled with sourcing risks and unverified claims.
The gap between promising animal data and verified human outcomes remains a critical hurdle, making rigorous clinical oversight and safe sourcing paramount for anyone exploring peptide therapeutics.
Ultimately, peptides represent a shift toward highly specific medicine, but unlocking their potential to treat neurological and immune decline safely requires bridging the gap between biohacking and clinical science.
Featuring
Listen to the full episode and explore every guest, topic, and moment on PodLume.